‹ ›
MYP_008403
← PREVIOUS NEXT → BACK
Basic Information
Ranalexin (7-20)
Anticancer
Anticancer ▸ Cytotoxic anticancer activity ▸ Cytotoxic
Antimicrobial
Antimicrobial ▸ Antibacterial
Toxicity / Safety ▸ Blood cell toxicity ▸ Hemolysis ▸ Hemolytic
Toxicity / Safety ▸ Cytotoxicity ▸ Cytotoxic
Venom / Toxin ▸ General toxin ▸ Cytotoxic
Standard
14 amino acids
C66H121N17O16S3
Standard
Sequence
KIVPAMICAVTKKC
Physicochemical Analysis
1504.97 Da
9.39
2.74
2.50
0.1955
0.99
0.39
0.21
18.61
111.43
0.0000
0.00
125.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
531.12
-2.97
20.0
22.0
50.0
102.0
1.0
13.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0209744 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Brevinin
32630
Structure & Mods
synthetic linear peptide [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Antimicrobial Antibacterial
Human prostate carcinoma C4-2
18 μg/mL
IC50
PMID29649587 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/29649587/
RECORD: Rec_0223890 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Brevinin
32630
Structure & Mods
synthetic linear peptide [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Antimicrobial Antibacterial
Human epidermoid cancer Hep2
35 μg/mL
IC50
PMID29649587 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/29649587/
RECORD: Rec_0227133 VERIFIED: YES
Provenance & Taxonomy
Synthetic construct [Synthetic]
32630
Structure & Mods
side-chain cyclized/stapled peptide [Cyclic]
canonical L-amino-acid peptide [L]
CH3(CH2)9CO, Undecanoic acid
None
Bio-Activity Profile
Antimicrobial Anticancer
MEC-7
35 μg/mL
IC50
PaperA novel tool against multiresistant bacterial pathogens: lipopeptide modification of the natural antimicrobial peptide ranalexin for enhanced antimicrobial activity and improved pharmacokinetics. Int J Antimicrob Agents. 2018 Jul;52(1):52-62. doi: 10.1016/j.ijantimicag.2018.03.023. PMID: 29649587. PMID29649587 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/29649587/
RECORD: Rec_0227632 VERIFIED: YES
Provenance & Taxonomy
Synthetic construct [Synthetic]
32630
Structure & Mods
side-chain cyclized/stapled peptide [Cyclic]
canonical L-amino-acid peptide [L]
CH3(CH2)8CO, Decanoic acid
None
Bio-Activity Profile
Antimicrobial Anticancer
Tumor cells: LNCaP C4-2
35 μg/mL
IC50
PaperA novel tool against multiresistant bacterial pathogens: lipopeptide modification of the natural antimicrobial peptide ranalexin for enhanced antimicrobial activity and improved pharmacokinetics. Int J Antimicrob Agents. 2018 Jul;52(1):52-62. doi: 10.1016/j.ijantimicag.2018.03.023. PMID: 29649587. PMID29649587 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/29649587/
RECORD: Rec_0227950 VERIFIED: YES
Provenance & Taxonomy
Synthetic construct [Synthetic]
32630
Structure & Mods
side-chain cyclized/stapled peptide [Cyclic]
canonical L-amino-acid peptide [L]
CH3(CH2)9CO, Undecanoic acid
None
Bio-Activity Profile
Antimicrobial Anticancer
Tumor cells: MEC-7
12 μg/mL
IC50
PaperA novel tool against multiresistant bacterial pathogens: lipopeptide modification of the natural antimicrobial peptide ranalexin for enhanced antimicrobial activity and improved pharmacokinetics. Int J Antimicrob Agents. 2018 Jul;52(1):52-62. doi: 10.1016/j.ijantimicag.2018.03.023. PMID: 29649587. PMID29649587 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/29649587/
FIRST PREV 1 ... 18 19 20 21 22 ... 40 NEXT LAST
Showing 5 records on this page · Page 20 of 40